Clinical trial · Interventional
Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)
NCT03199989CI-TRIAL-00043858EPAC1unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to design a prospective randomized clinical trial to explore whether postoperative adjuvant chemotherapy may provide survival benefit for stage II colon cancer patients with high risk factors.Therefore the investigators can provide high level clinical evidence of indications for patients with colon cancer with stage II colon cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adjuvant Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CapeOX（Capecitabine+Oxaliplatin） | Drug | — | UNRESOLVED |
| Observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- adjuvant chemotherapy group
- description
- patients enrolled int the adjuvant chemotherapy group will receive adjuvant chemotherapy\[CapeOX（Capecitabine+Oxaliplatin）\] by the current guidelines
- interventionNames
- Drug: CapeOX（Capecitabine+Oxaliplatin）
- type
- EXPERIMENTAL
- label
- observation group
- description
- patients enrolled int the adjuvant chemotherapy group will not receive adjuvant chemotherapy just for observation
- interventionNames
- Other: Observation
Primary outcomes (1)
- measure
- 3-year disease free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. aged 18 to 75 years; 2. pathologically confirmed adenocarcinoma of the colon 3. after curative resection pathological stage was T3-4N0M0; 4. with at least one of the following factors: 1. T4 staging 2. lymph nodes number less than 12 3. poor differentiation (except MSI-H) 4. LVI or PNI 5. obstruction or perforation 6. Elevated preoperative serum CEA 5. ECOG Performance status 0-1 6. no evidence of distant metastases 7. no preoperative chemotherapy or chemoradiation therapy 8. ANC \> 1.5 cells/mm3, HGB \> 10.0 g/dL, PLT \> 100,000/mm3, total bilirubin ≤ 1.5 xULN, AST≤ 3 x ULN, ALT ≤ 3 x ULN. 9. Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study. Exclusion Criteria: 1. combined with other cancer 2. Creatinine level greater than 1.5 times the upper limit of normal. 3. Patients who have received preoperative chemotherapy or chemoradiotherapy. 4. Patients with a history of a prior malignancy within the past 5 years. 5. Women who are pregnant or breast-feeding. 6. patients may not complete the whole schedule of chemotherapy 7. Patients with any other concurrent medical or psychiatric condition or disease which would make them inappropriate candidates for entry into this study.
References
Publications (0)
Data not yet available
No reference posted for this study.